IN2012DN02368A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02368A IN2012DN02368A IN2368DEN2012A IN2012DN02368A IN 2012DN02368 A IN2012DN02368 A IN 2012DN02368A IN 2368DEN2012 A IN2368DEN2012 A IN 2368DEN2012A IN 2012DN02368 A IN2012DN02368 A IN 2012DN02368A
- Authority
- IN
- India
- Prior art keywords
- langerin
- present
- peptides
- isolated anti
- antibody
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24228309P | 2009-09-14 | 2009-09-14 | |
PCT/US2010/048800 WO2011032161A2 (en) | 2009-09-14 | 2010-09-14 | Vaccines directed to langerhans cells |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02368A true IN2012DN02368A (es) | 2015-08-21 |
Family
ID=43733140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2368DEN2012 IN2012DN02368A (es) | 2009-09-14 | 2010-09-14 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20110081343A1 (es) |
EP (1) | EP2477655A4 (es) |
JP (2) | JP2013504599A (es) |
CN (1) | CN102711824A (es) |
AR (1) | AR078423A1 (es) |
AU (1) | AU2010291939B2 (es) |
BR (1) | BR112012005713A2 (es) |
CA (1) | CA2774140A1 (es) |
IN (1) | IN2012DN02368A (es) |
MX (1) | MX2012003058A (es) |
TW (1) | TWI483734B (es) |
WO (1) | WO2011032161A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103415534A (zh) | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
CN102741295A (zh) | 2009-03-10 | 2012-10-17 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
BRPI1009455A2 (pt) | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
TWI483734B (zh) | 2009-09-14 | 2015-05-11 | Baylor Res Inst | 針對蘭格漢氏細胞(langerhans cells)之疫苗 |
KR20130036246A (ko) | 2010-05-07 | 2013-04-11 | 베일러 리서치 인스티튜트 | 사람 cd8+ t 세포의 수지상 세포 면역수용체(dcir)-매개 교차프라이밍 |
WO2012129227A1 (en) * | 2011-03-22 | 2012-09-27 | Baylor Research Institute | Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine |
TW201300418A (zh) | 2011-03-25 | 2013-01-01 | Baylor Res Inst | 用於抗c型肝炎病毒免疫之組合物及方法 |
AR088428A1 (es) * | 2011-08-25 | 2014-06-11 | Baylor Res Inst | Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos |
US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
EP3013362B1 (en) | 2013-06-28 | 2021-08-04 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
PE20171142A1 (es) * | 2013-11-01 | 2017-08-10 | Pfizer | Vectores para expresion de antigenos asociados a prostata |
CA2936833A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
US10906972B2 (en) * | 2015-02-12 | 2021-02-02 | Tohoku University | Cancer cell specific anti-podocalyxin antibody and method for producing same |
WO2017120280A1 (en) * | 2016-01-06 | 2017-07-13 | Virginia Tech Intellectual Properties, Inc. | Antigen targeting to porcine langerin |
US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
WO2017167217A1 (en) | 2016-04-01 | 2017-10-05 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
CN109312402A (zh) * | 2016-04-11 | 2019-02-05 | 得克萨斯州大学系统董事会 | 用于检测单个t细胞受体亲和力和序列的方法和组合物 |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
CN112074298A (zh) * | 2018-01-18 | 2020-12-11 | 马克斯·普朗克科学促进协会 | Langerin+细胞靶向 |
BR112022024063A2 (pt) | 2020-05-26 | 2023-01-31 | Inst Nat Sante Rech Med | Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina |
CN111850004B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种活性提高的纤维小体对接蛋白突变体36740及应用 |
MX2023005570A (es) | 2020-11-12 | 2023-05-29 | Inst Nat Sante Rech Med | Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion. |
MX2023007610A (es) | 2020-12-23 | 2023-07-12 | Inst Nat Sante Rech Med | Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno. |
MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inserm Institut National De La Sante Et De La Rech Medicale | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
TWI815572B (zh) * | 2021-09-27 | 2023-09-11 | 美商圖策智能科技有限公司 | 特定病毒的突變耐受表位的推估方法及系統 |
WO2023088968A1 (en) | 2021-11-17 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Universal sarbecovirus vaccines |
CN117343178A (zh) * | 2022-07-04 | 2024-01-05 | 王昭 | 一种结合人cd207的抗体、抗人cd207的嵌合抗原受体及其应用 |
WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685930B1 (en) * | 1991-03-27 | 2004-02-03 | Tanox, Inc. | Methods and substances for recruiting therapeutic agents to solid tumors |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
MXPA02010869A (es) * | 2000-05-08 | 2003-04-14 | Medarex Inc | Anticuerpos monoclonales humanos para celulas dendriticas. |
US7560534B2 (en) * | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
KR100480985B1 (ko) | 2000-05-19 | 2005-04-07 | 이수화학 주식회사 | 표피 성장 인자 수용체에 대한 사람화된 항체 |
US7247615B2 (en) * | 2001-11-30 | 2007-07-24 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen and uses therefor |
CA2517926A1 (en) * | 2003-03-04 | 2004-10-28 | Alexion Pharmaceuticals, Inc. | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
AU2004281634B2 (en) * | 2003-09-03 | 2011-01-27 | Dendritherapeutics, Inc. | Multiplex vaccines |
WO2006127150A2 (en) | 2005-04-08 | 2006-11-30 | Argos Therapeutics, Inc. | Dendritic cell compositions and methods |
CA2715042C (en) * | 2007-02-02 | 2021-02-02 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
WO2009061996A2 (en) * | 2007-11-07 | 2009-05-14 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
ES2890230T3 (es) * | 2008-07-16 | 2022-01-18 | Baylor Res Institute | Vacuna contra el VIH basada en el direccionamiento de Gag y Nef maximizado a células dendríticas |
CN103415534A (zh) * | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
TWI483734B (zh) | 2009-09-14 | 2015-05-11 | Baylor Res Inst | 針對蘭格漢氏細胞(langerhans cells)之疫苗 |
-
2010
- 2010-09-14 TW TW099131140A patent/TWI483734B/zh not_active IP Right Cessation
- 2010-09-14 AR ARP100103355A patent/AR078423A1/es unknown
- 2010-09-14 US US12/882,052 patent/US20110081343A1/en not_active Abandoned
- 2010-09-14 IN IN2368DEN2012 patent/IN2012DN02368A/en unknown
- 2010-09-14 BR BR112012005713A patent/BR112012005713A2/pt not_active IP Right Cessation
- 2010-09-14 EP EP10816281.9A patent/EP2477655A4/en not_active Withdrawn
- 2010-09-14 JP JP2012528993A patent/JP2013504599A/ja active Pending
- 2010-09-14 WO PCT/US2010/048800 patent/WO2011032161A2/en active Application Filing
- 2010-09-14 AU AU2010291939A patent/AU2010291939B2/en not_active Ceased
- 2010-09-14 CN CN2010800515192A patent/CN102711824A/zh active Pending
- 2010-09-14 MX MX2012003058A patent/MX2012003058A/es not_active Application Discontinuation
- 2010-09-14 CA CA2774140A patent/CA2774140A1/en not_active Abandoned
-
2013
- 2013-04-15 US US13/863,131 patent/US9315580B2/en active Active
-
2014
- 2014-12-25 JP JP2014261438A patent/JP2015110582A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2011032161A2 (en) | 2011-03-17 |
MX2012003058A (es) | 2012-05-22 |
WO2011032161A8 (en) | 2011-07-07 |
WO2011032161A3 (en) | 2011-08-25 |
TWI483734B (zh) | 2015-05-11 |
EP2477655A4 (en) | 2014-02-12 |
CA2774140A1 (en) | 2011-03-17 |
JP2015110582A (ja) | 2015-06-18 |
CN102711824A (zh) | 2012-10-03 |
US20110081343A1 (en) | 2011-04-07 |
AU2010291939A1 (en) | 2012-04-05 |
US20140030264A1 (en) | 2014-01-30 |
US9315580B2 (en) | 2016-04-19 |
EP2477655A2 (en) | 2012-07-25 |
JP2013504599A (ja) | 2013-02-07 |
AR078423A1 (es) | 2011-11-09 |
BR112012005713A2 (pt) | 2019-09-24 |
TW201116295A (en) | 2011-05-16 |
AU2010291939B2 (en) | 2012-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02368A (es) | ||
PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
PH12017500890A1 (en) | Antibody drug conjugates | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
MY181648A (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
MX2021001098A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
MX2016008667A (es) | Inmunoglobulina con fab en tandem y usos de esta. | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
EA201100268A1 (ru) | Вакцина | |
EA030777B9 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
BR112016030183A2 (pt) | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos | |
NZ700823A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
WO2010002478A3 (en) | Glycopeptide and uses thereof | |
WO2012088247A3 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
MX2019002968A (es) | Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal. | |
MX2021005373A (es) | Variantes de proteinas de union al factor h y metodos de uso de estas. | |
WO2011063235A3 (en) | Peptides, devices, and methods for the detection of ehrlichia antibodies | |
MX2014000531A (es) | Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13. | |
WO2014131019A3 (en) | Her-1, her-3 and igf-1r compositions and uses thereof | |
EA201990218A1 (ru) | Антитела с низкой иммуногенностью и их применения | |
NZ731491A (en) | Cd83 binding proteins and uses thereof |